Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
HH hopefully so, as they cant keep the SP this low for much longer. The buying against sells needs to be greater very soon. When its let off the lead, think it will relate very quickly and probably double SP leaving a whole to be filled
But the way the market has taken the last lot of news, i wouldnt be surprised that the SP is held down again. Someone or numerous others are manipulating the SP. Think it is to do with them thinking Vlad is trying to get a raise away at higher prices.
Look at RNS on the 28th Jun about funding and see what it says about what the funds were being used for used. Then suddenly another placing for more funds. To be utilised for Turkey again and the Portland.. Stop pulling the wool over shareholders SS as you said that Turkey was already fully funded.
Looks like someone is offloading to get rid of their short position, wouldn’t be surprised if it isn’t to do with our relevant donkey across on ADVFN. Probably try to drive the price down again and get other weak holders to sell on a loss.
Has anyone realised if Lilly were to come in with a cheap takeover bid, there would be a counter offer from the other GlobalCo (If this is not Lilly also, i still think this has a link with a Belgium Pharma, so Novartis, Jannsen Cilag, Glaxo, Pfizer or AstraZeneca). Then it will go to a takeover war......
Pumpky to file an IND to the FCA can take upto a year. By the way what you are saying is totally wrong about how long it takes. As you quoted yourself it was a GOAL of the company to file the IND to FCA, this could have been a 6month, 12month, 24month, 36month Goal who knows!!
Just listened to the interview and very revealing. As i said over a year ago, that there was definitely more than 2 x GlobalCo’s, we already know Eli Lilly is one. So a lot of things in the pipeline in the next few weeks or months. Happy times just around he corner
Digitt i think you need to read the RNS from the 3rd Feb, which states "The Company intends to use the remainder of the received funds from the Financing Facility for the development of its other product candidates. For example, the Company may use these funds to complete IND-enabling pre-clinical studies for its CDX antibody, if necessary, in the event that GlobalCo declines to exercise its option to license the intellectual property necessary to exploit the CDX antibody, as discussed above. If, in the alternative, these funds are not needed for CDX antibody development, the Company will deploy such funds for the development of its other product candidates, including the further development of its CBR Platform, as well as for general working capital purposes.